drugset / Trial / NCT00430235
A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Purpose: To determine the efficacy of BAY 43-9006 in combination with bicalutamide in patients with chemo-naïve hormone-refractory prostate cancer. Hypothesis: That there will be PSA response when BAY 43-9006 in combination with bicalutamide is given to patients with chemo-naïve hormone-refractory prostate cancer.
Timeline
- Start
- 2007-03
- Primary completion
- 2010-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Background | Bicalutamide | Other / unclassified | 50 mg | Oral |